Elevance Health (ELV)
NYSEHealth CareMedical - Healthcare PlansSnapshot 2026-11-04
$434.18+4.94%
Close 2026-11-04 · 1-day change
NYSEHealth CareMedical - Healthcare PlansSnapshot 2026-11-04
Research Workspace
Put ELV beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisRevenue growth is slowing — up about 4% over the past year and decelerating.
View GrowthRanks among the strongest in its industry on quality — around the top 21%.
View QualityManagement screens strong on capital allocation, earnings delivery, margins.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskElevance Health's strong earnings performance supports its valuation. Revenue growth is slowing, with Q3 up just 0.7% year over year. The company beat Q3 estimates by 50% and raised its 2026 guidance. It trades at 14x earnings, well below the 22x peer median. The price reflects modest growth expectations relative to our view. A guidance cut after a recent raise would be a major negative. Peer multiples imply a price about 10% above where it trades. Our read remains intact, though this read is provisional.
Trailing returns as of 2026-11-04. ELV is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 22 analysts currently covering ELV (as of Nov 2026).
Based on 14 Wall Street analysts offering 12-month price targets for ELV in the last 4 months.
Continue this research
Compare ELV with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| ELV Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 11 valuation methods, at three horizons. As of 2026-11-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Managed Health Care — fair value, gap to price, and forward P/E.
Compare the value case
Put ELV next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Raise FY 2026 adjusted diluted EPS guidance
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-11-04. EPS is implied from price ÷ P/E. Not investment advice.
Current $434.18
The last 12 months of price, then the range of analyst 12-month targets from today’s $434.18.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Higher 2026 EPS guidance and a 2027 growth target directly advance the earnings objective.
Advances: Raise FY 2026 adjusted diluted EPS guidance
Raised yearly outlook alongside higher profit and revenue supports the FY 2026 EPS objective.
Advances: Raise FY 2026 adjusted diluted EPS guidance
Higher profit as costs ease supports earnings, though the headline does not specify guidance.
Advances: Raise FY 2026 adjusted diluted EPS guidance
Reported estimate beat and raised guidance support the FY 2026 EPS objective.
Advances: Raise FY 2026 adjusted diluted EPS guidance
Growth plan confirmation supports EPS guidance objective.
Advances: Raise FY 2026 adjusted diluted EPS guidance
Reaffirmation supports growth in adjusted diluted EPS guidance.
Advances: Raise FY 2026 adjusted diluted EPS guidance
Increased investor confidence supports EPS growth objectives.
Earnings outperforming indicates strong financial health.